Cargando…

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool

BACKGROUND: Fecal microbiota transplantation (FMT) is vulnerable to emerging pathogens due to reliance on donor screening for risk mitigation. These concerns were highlighted by dual FDA safety alerts regarding FMT transmission of bacterial pathogens, which were recognized in hindsight only after ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	McChalicher, Christopher, Abdulaziz, Ahmad, Halvorsen, Elizabeth, Lombardo, Mary-Jane, Winkler, Jonathan, Almomani, Sanabel, McGovern, Barbara, McKenzie, Gregory, Ege, David, Aunins, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690818/ http://dx.doi.org/10.1093/ofid/ofab466.1229

Ejemplares similares

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2022)

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
por: McChalicher, Christopher W J, et al.
Publicado: (2023)

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
por: Ford, Christopher, et al.
Publicado: (2018)

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
por: Henn, Matthew, et al.
Publicado: (2018)

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

Complications of bronchoscopy for foreign body removal: experience in 1035 cases
por: Hasdiraz, Leyla, et al.
Publicado: (2006)

Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
por: Henn, Matthew, et al.
Publicado: (2017)

La experiencia de los petroleros del golfo, 1904-1035
por: Urbán Sánchez, Cecilia Rosario
Publicado: (2002)

P1035: COUNTRY DIFFERENCES IN THE BURDEN OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE
por: Hwee, J., et al.
Publicado: (2022)

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Sonate, für flöte und basso continuo. E-Dur BWV 1035

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

1035. Implementation of an Antimicrobial Stewardship Program-Led, Multifactorial Pneumonia Diagnosis and Treatment Bundle
por: Cua, Jefferson L, et al.
Publicado: (2019)

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines
por: Malacrida, Alessio, et al.
Publicado: (2022)

1035 New Urine Reporting Criteria to Accurately Report Nosocomial Clinical Urinary Tract Infection
por: Schora, Donna, et al.
Publicado: (2014)

Immunochemical specificity of the combining site of murine myeloma protein CAL20 TEPC1035 reactive with dextrans
Publicado: (1981)

1035. Differentiation Between True Infection and Contamination of Coagulase-Negative Staphylococci by Developing a Prediction Rule
por: Fujino, Takahisa, et al.
Publicado: (2018)

An Exploration of the Psycho-Social Benefits of Providing Sponsorship and Supporting Others in Traditional 12 Step, Self-Help Groups
por: McGovern, William, et al.
Publicado: (2021)

Systematization of Oncoplastic Surgery: Selection of Surgical Techniques and Patient-Reported Outcome in a Cohort of 1,035 Patients
por: Rezai, Mahdi, et al.
Publicado: (2015)

1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results
por: Chounta, Vasiliki, et al.
Publicado: (2020)

1035. The Microbiological Pattern and Outcome of Community Acquired Brain Abscess: A Single Centre Study from Pakistan
por: Sayeed, Muneeba A
Publicado: (2022)

SG-APSIC1035: Prospective safety surveillance study of ACAM2000 smallpox vaccine in deployed military personnel
por: Yeo, Kevin, et al.
Publicado: (2023)

MB109 as bioactive human bone morphogenetic protein-9 refolded and purified from E. coli inclusion bodies
por: Kuo, Mario Meng-Chiang, et al.
Publicado: (2014)

Environmental and occupational respiratory diseases -1035. Isolation and purification of major allergenic protein of moth and rice weevil insect extracts
por: Kausar, Mohd Adnan, et al.
Publicado: (2013)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

Draft Genome Sequences from Cyclospora cayetanensis Oocysts Purified from a Human Stool Sample
por: Qvarnstrom, Yvonne, et al.
Publicado: (2015)

Thriving in the gig economy: how to capitalize and compete in the new world of work
por: McGovern, Marion
Publicado: (2017)

Taking a Bite Out of Amalgam Concerns?: Study Shows No Renal Effects in Children
por: McGovern, Victoria
Publicado: (2008)

A Twist in the Ritalin Riddle: Drug-Related Genomic Damage Not Confirmed in Children
por: McGovern, Victoria
Publicado: (2007)

Signs for Girls: Biomarkers of Common Exposures
por: McGovern, Victoria
Publicado: (2007)

Aging: Shedding Light on Vitamin D Deficiency in Women
por: McGovern, Victoria
Publicado: (2004)

Spraying on a Summer Night: A Safer Way to Stop West Nile Virus
por: McGovern, Victoria
Publicado: (2004)

Asthma: Bowled Over by Dust
por: McGovern, Victoria
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_hn2ojr04v0q2cbpbp4i3aove1m